Characterization of molecular pathways mediating the effects of novel therapeutic agents in heart failure
Heart failure (HF) is a condition that develops after the heart becomes damaged or weakened. HF occurs when the pumping action of the heart is not strong enough to move blood around, especially during increased activity or under stress. In addition, the heart muscle may not relax properly to accommodate the flow of blood back from the lungs to the heart. These abnormalities in heart function can cause fluid to back up in lungs and in other parts of body. More than 30% of subjects with HF develop pulmonary hypertension (PH); a condition associated with a poor quality of life and reduced survival. PH associated with left heart disease (LHD), classified as group II PH, is most common in patients with HF: those with HF with preserved ejection fraction (HFpEF) and those with reduced ejection fraction (HFrEF).There is however currently no therapy that can selectively target the molecular processes responsible for PH due to LHD and these subjects still unfortunately progress to right ventricular failure and death. PBI-4050 and PBI-4547 are a novel therapeutic agents developed by ProMetic targeting an orphan receptor that is highly expressed in lung tissues of animals with HF.